← Back to headlines
Stifel Initiates Sutro Biopharma Stock with Buy Rating on ADC Platform
Stifel has begun its coverage of Sutro Biopharma stock with a 'buy' rating, citing confidence in the company's Antibody-Drug Conjugate (ADC) platform.
6 Aug, 20:55 — 6 Aug, 20:55
Sources
Showing 1 of 1 sources
